CAR-T trial deaths do not deter lupus patients hoping for a cure

Lupus patients are continuing to seek experimental CAR-T cell therapies despite recent clinical trial deaths linked to major pharmaceutical companies. Patients facing severe, treatment-resistant disease view the potential for a cure as worth the significant risks involved.
Why it matters
The situation underscores the desperate need for effective treatments for autoimmune diseases and the complex ethical balance between patient autonomy and clinical safety.
Lupus patients struggling with the debilitating disease are lining up to try experimental CAR-T therapies even after the recent deaths of four patients in clinical trials for a variety of autoimmune diseases, according to doctors who treat the life-threatening condition. The trials remain halted and full details of the deaths — three linked to Novartis and one to Bristol Myers Squibb — have not been released. Still, patients are willing to take the risk, compelled by accounts of people with advanced disease who were able to stop all medications and reclaim normal lives. “I have patients that are literally waiting to get in,” said Dr. Anca Askanase, chief of rheumatology at the Hospital for Special Surgery in New York, who has enrolled patients in the Bristol Myers CAR-T trials.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in